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Abstract
Purpose Axitinib, a potent and selective inhibitor of vas-
cular endothelial growth factor receptors 1, 2, 3, is metabo-
lized by cytochrome P450 3A4 and glucuronidation. This
study evaluated the eVect of rifampin, a potent inducer of
drug-metabolizing enzymes, on axitinib plasma pharmaco-
kinetics. Equal numbers of Japanese and Caucasian sub-
jects were enrolled to assess the potential diVerences in
axitinib pharmacokinetics between the two ethnicities.
Methods Forty healthy volunteers were randomized to
receive 5 mg axitinib alone and with 600 mg rifampin.
Results Rifampin expectedly decreased AUCinf and Cmax
of axitinib (geometric mean reduced by 79 and 71%,
respectively). However, diVerences in axitinib pharmacoki-
netics were not observed between Japanese and Caucasian
subjects (geometric mean ratios for axitinib treatment alone
for AUCinf and Cmax were 103 and 96%).
Conclusions The results support a common axitinib start-
ing dose in both populations. Potent inducers of drug-
metabolizing enzymes reduce axitinib exposure and dose
adjustments may be needed for optimal eYcacy.
Keywords Anticancer agents · Pharmacokinetics · 
Healthy volunteers · Ethnic groups · Plasma drug 
concentrations · Adverse drug events
Introduction
Axitinib (AG-013736) is an oral, potent, and selective
inhibitor of vascular endothelial growth factor receptors 1,
2, 3 [1]. Early clinical trial experience in over 500 cancer
patients has demonstrated that it has activity and is well-tol-
erated as a single agent [2–4] and in combination with vari-
ous chemotherapeutic regimens [5, 6]. Axitinib is currently
in phase III development for advanced renal cell carcinoma
and in phase II development for various other tumor types.
Clinically, axitinib is administered 5 mg twice daily as
an oral starting dose and its pharmacokinetics are character-
ized by rapid oral absorption (with peak plasma concentra-
tions occurring 1–2 h after dosing in the fasted state) and a
terminal plasma half-life of 3–5 h. Axitinib has an oral
absolute bioavailability of approximately 58% (PWzer Inc.,
Data on Wle 2008) with generally linear pharmacokinetics
[7].
Axitinib is primarily metabolized by cytochrome P450
(CYP) 3A4 and to a lesser extent by CYP1A2, CYP2C19
and uridine diphosphate glucuronosyltransferase (UGT)
1A1 [6]. Therefore, axitinib plasma exposure has the
potential to be aVected by the co-administration of drugs
that inhibit or induce CYP3A. This has been previously
observed with the co-administration of CYP3A inhibitor
ketoconazole, which increased the area under the plasma
concentration–time curve from time 0 to 24 h (AUC(0–24))
and maximal plasma concentration (Cmax) of axitinib
approximately 2- and 1.5-fold, respectively [8]. Rifampin
is a known potent CYP3A4 inducer along with other
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drug-metabolizing enzymes including CYP1A2 and
UGT1A1, and is hence likely to aVect the pharmacokinetics
of axitinib [9–11]. In addition, subjects who are homozy-
gous for UGT1A1*28 variant gene have the potential for
reduced glucuronidation of axitinib. Due to diVerences in
the frequency of UGT1A1*28 genotype between Cauca-
sians (12%, range 9–16%) and Japanese (4%, range 1–6%)
[12–22], this may also contribute to diVerences in the
pharmacokinetics between these ethnicities.
The primary objective of this phase I study was to
investigate potential pharmacokinetic interaction in healthy
volunteers when axitinib is administered in combination
with rifampin. Secondary objectives included: (1) assessing
potential inter-ethnic diVerences between Caucasian and
Japanese subjects, (2) evaluating the eVect of UGT1A1
genotype on the pharmacokinetics of axitinib, (3) evaluat-
ing the safety and tolerability of axitinib alone and when
co-administered with rifampin.
Methods
Subjects
This study was conducted in compliance with the ethical
principles originating in or derived from the Declaration
of Helsinki (Revised Edinburgh, 2000) and in accordance
with all International Conference on Harmonization
and Good Clinical Practice guidelines. The Wnal protocol
and informed consent documentation were reviewed and
approved by the Institutional Review Board at the study
center (Radiant Covance, Hawaii, USA).
Key inclusion criteria included: female of non-childbear-
ing potential or male, age 18–55 years; Caucasian or Wrst-
generation Japanese (both parents of Japanese descent, born
in Japan and resident outside of Asia for ·5 years); and
body mass index 18–28 kg/m2 with total body weight
>45 kg (99 lb). Key exclusion criteria included: clinically
signiWcant medical or surgical conditions with the potential
to interfere with the absorption, distribution, metabolism or
excretion of the study drugs; history of alcohol consump-
tion >14 drinks/week for men or 7 drinks/week for women
within 6 months of screening; smoker; electrocardiogram
(ECG) abnormality; blood pressure >140/90 mmHg on
two evaluations at least 10 min apart; and treatment with
an investigational drug or any known CYP450 enzyme-
inducing/-inhibiting agents or herbal supplements within
30 days prior to Wrst dose of study medication. Subjects
were to abstain from using prescription and non-prescrip-
tion drugs (other than acetaminophen as deemed neces-
sary), vitamins and dietary supplements within 7 days
prior to the Wrst dose of study medication and throughout
the study.
Treatments
This single-center, open-label study involved subjects
being assigned to two separate treatment sequences accord-
ing to a two-way crossover design. The two treatments
involved subjects receiving single 5 mg axitinib as an oral
dose on day 1 (treatment A), and subjects receiving rifam-
pin (Rifadin®, Aventis Pharmaceuticals Inc., Bridgewater,
NJ, USA) 600 mg/day orally for 9 days with a single 5 mg
oral dose of axitinib co-administered on day 8 (treatment
B). In both treatment arms, axitinib was administered in the
morning after an overnight fast of at least 10 h. To stan-
dardize conditions, subjects were not allowed to eat or
drink (except water) for at least 4 h following dosing. To
ensure full compliance, all doses of study medication were
administered under medical supervision at the clinic.
Subjects received treatments A and B according to a
crossover design. Volunteers initially receiving treatment A
adhered to a 7-day washout period before commencing
treatment B; those initially receiving treatment B adhered to
a 21-day washout before treatment A began. Washout was
required to allow elimination of axitinib from plasma and
for recovery from rifampin-mediated enzyme induction.
Study assessments
Sample collection
Blood samples (5 mL) for determination of axitinib plasma
concentration were collected pre-dose and at 0.5, 1, 1.5, 2,
4, 6, 8, 12, 16, 24 and 32 h following axitinib administra-
tion on both treatment arms.
Bioanalytical methods
Plasma concentrations of axitinib were measured using a
validated high-performance liquid chromatography with
tandem mass spectrometric detection method (Charles
River Discovery and Development Services; Worcester,
MA, USA) [7]. The limit of quantiWcation for the axitinib
assay in plasma was 0.1 ng/mL, the between-day precision
was <15.7% and bias <12.8% for quality control samples
evaluated in the concentration range of interest. Pharmaco-
dynamic evaluations consisted of the ratio of urinary 6,
-hydroxycortisol/cortisol concentrations as a marker of
CYP3A4 induction [23]. The limit of quantiWcation for the
cortisol assay in urine was 2.5 ng/mL, the between-day
precison was <12.5% and the bias was <15%. For 6,
-hydroxycortisol in urine, the limit of quantiWcation
was 12.5 ng/mL, the between-day precision was <8.7% and
bias was <16%. The urinary 6, -hydroxycortisol/cortisol
ratio was calculated for all subjects. During treatment A,
urine samples were collected pre-dose (baseline). DuringCancer Chemother Pharmacol (2010) 65:563–570 565
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treatment B, urine samples were collected pre-dose (baseline)
and in the morning on days 8 and 9 following combination
treatment with axitinib and rifampin. Urine concentrations
of cortisol and 6, -hydroxycortisol were determined using
a validated high-performance liquid chromatography
method with tandem mass spectrometric detection (ABC
Laboratories; Columbia, MO, USA).
Genotyping
To assess possible diVerences in metabolism, subjects were
genotyped for metabolizing enzymes including UGT1A1.
DNA was extracted from whole blood using Qiagen’s QIA-
amp kit. The polymerase chain reaction was used to amplify
DNA samples. The Sequenom MassArray was used to perform
the genotyping of the UGT1A1*28 (Sequenom Discovery)
genotyping assay. The genotypes were determined with
MassARRAY RT™ software (SpectroTYPER™ Version 3.4,
Sequenom). The UGT1A1*28 genotype was investigated as
an exploratory variable to determine the potential correlation
with pharmacokinetic variability. SpeciWcally, the variants of
UGT1A1 to be assessed included UGT1A1*60, UGT1A1-
3156 (¡3156 G!A nucleotide change), UGT1A1 promoter
TA repeat (*28, *36, *37), UGT1A1*6 and UGT1A1*27.
Safety
Adverse event (AE) monitoring, vital signs (heart rate and
blood pressure), 12-lead ECG recordings, and clinical labo-
ratory tests were carried out. AE severity was based on the
National Cancer Institute Common Terminology Criteria
for Adverse Events criteria; relationship to treatment was
determined by the investigator.
Pharmacokinetic and statistical evaluations
The pharmacokinetic evaluation of axitinib was performed
with WinNonlin (Version 4.01, Pharsight, Mountain View,
CA) using a non-compartmental approach. Pharmacoki-
netic parameters estimated for orally administered axitinib
included AUC from time zero extrapolated to inWnity
(AUCinf) and from time zero to the time for the last quanti-
Wable concentration (AUClast), Cmax, time to Cmax (Tmax),
terminal half-life, oral clearance and apparent volume of
distribution. Pharmacokinetic parameters were summarized
by treatment, ethnicity and genotype.
For the parameters AUCinf, AUClast and Cmax, a statisti-
cal analysis to determine the estimated ratio of adjusted
geometric means and the associated 90% conWdence inter-
val (CI) was performed. A sample size of 32 subjects was
determined to have suYcient power to detect treatment
diVerences in AUCinf and Cmax. An additional eight subjects
were enrolled to account for possible dropouts.
Fig. 1 a Mean (§standard deviation) axitinib plasma concentration
proWle in subjects administered axitinib alone (open symbols) (n = 40),
and co-administered axitinib and rifampin (closed symbols) (n = 39)
(Inset same plot with y-axis on log scale). b Comparative box plot of
axitinib area under the plasma concentration–time curve from 0 h to inWn-
ity (AUCinf; ng h/mL) in all subjects in the absence (n = 40) and pres-
ence (n = 39) of rifampin. c Comparative box plot of axitinib maximal
plasma concentration (Cmax; ng/mL) in all subjects in the absence (n =
40) and presence (n = 39) of rifampin. Box plot represents 25th and 75th
percentiles, whiskers extend to 5th and 95th percentiles. Median is indi-
cated by line within box. Circles represent values for individual subjects
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Results
Subjects
A total of 40 male subjects (Caucasian, n = 20; Japa-
nese, n = 20) with a mean (§standard deviation) age of
29 (§7.6) years (range 21–52 years) and a mean weight
of 72.3 (§9.5) kg (range 54.0–96.7 kg) were enrolled.
During the enrollment period of 6 months for this study,
no women of non-childbearing potential who otherwise
met study entry criteria were found; hence, only male
subjects eventually were enrolled in this study. One sub-
ject failed to complete both treatment periods for rea-
sons unrelated to treatment (failed drug test) but was
included in the evaluable population. Hence, all subjects
(n = 40) received at least one axitinib 5 mg oral dose and
39 subjects received axitinib and rifampin combination
therapy.
CYP3A4 induction
The mean urinary 6, -hydroxycortisol/cortisol ratio was
4.2 § 3.5 at baseline and increased to 18.6 § 15.8 after
8 days of rifampin dosing. After cessation of rifampin treat-
ment, the mean 6, -hydroxycortisol/cortisol ratio returned
to near baseline values (4.6 § 3.4). Similar results were
observed in Caucasian and Japanese subjects. In Caucasian
subjects, mean 6, -hydroxycortisol/cortisol ratio was
4.5 § 2.6 at baseline and increased to 15.3 § 9.1 after
8 days of rifampin dosing and in Japanese subjects the
mean ratio was 4.0 § 4.3 at baseline and 21.7 § 20.0 after
8 days of rifampin dosing.
Pharmacokinetics
The plasma concentration–time proWles of axitinib in the
absence and presence of rifampin are shown in Fig. 1a. Axi-
tinib plasma concentrations were reduced when co-adminis-
tered with rifampin. Axitinib pharmacokinetic parameters
for the entire evaluable subject population are reported in
Table 1 and Fig. 1b, c. Geometric means of AUCinf and
AUClast for axitinib were decreased by 79 [geometric mean
ratio 21% (90% CI 18–24)] and 80% [geometric mean ratio
20% (90% CI 17–23)] respectively, when co-administered
with rifampin. The geometric mean for axitinib Cmax was
reduced by 71% when co-administered with rifampin [geo-
metric mean ratio 29% (90% CI 24–35)]. The axitinib
plasma half-life appeared to be decreased in the presence of
rifampin (Table 1); however this should be interpreted with
caution since this is likely due to axitinib plasma concentra-
tions falling below the limit of quantiWcation at later time-
points in the presence of rifampin which resulted in poorly
estimated terminal half-life in many subjects.
EVect of ethnicity on axitinib pharmacokinetics
Axitinib pharmacokinetics were comparable between Cau-
casian and Japanese subjects in the presence and absence of
rifampin (Table 2; Figs. 2, 3). The geometric mean ratio
(Japanese versus Caucasian) for axitinib AUCinf and Cmax
was 103 (90% CI 71–151) and 96% (90% CI 64–144)
respectively. When axitinib was administered alone,
median peak plasma concentrations of axitinib were
achieved in 1.5 h (range 1.5–2 h) after dosing in Caucasian
volunteers and 1.75 h (range 0.5–2 h) in Japanese subjects
Table 1 Mean axitinib plasma pharmacokinetic parameters
AUCinf area under the plasma concentration–time curve from 0 h to inWnity, AUClast area under the plasma concentration–time curve from 0 h to
last quantiWable concentration, CI conWdence interval, CL/F apparent oral clearance, Cmax maximal plasma concentration following single-dose
administration, t1/2 plasma elimination terminal half-life, Tmax time to maximal plasma concentration, Vz/F apparent volume of distribution during
the elimination phase
a Geometric means (95% CI) for AUCinf, AUClast, Cmax, CL/F and Vz/F, arithmetic means (%CV) for t1/2 and median (range) for Tmax
b n = 39, unless otherwise speciWed
c n = 38 because parameter could not be estimated for one subject with a non-estimable elimination half-life
d Ratio of axitinib in combination with rifampin versus axitinib alone
Parameter (units)a Axitinib 5 mg 
(n =4 0 )
Axitinib 5 mg + rifampin 
600 mg/day (n =3 9 b)
Ratio of adjusted 
meansd, % 
(90% CI)
AUCinf (ng h/mL) 190 (152–238) 40 (31–53)c (n = 38) 21 (18–24)
AUClast (ng h/mL) 187 (149–235) 37 (28–50) 20 (17–23)
Cmax (ng/mL) 50.1 (39.5–63.7) 14.5 (10.6–19.8) 29 (24–35)
Tmax (h) 1.5 (0.5–4) 1.5 (1–4)
t1/2 (h) 7.7 (145) 2.5 (188)c (n = 38)
CL/F (L/h) 26.3 (21.0–32.9) 123.5 (95.0–160)c (n =3 8 )
Vz/F(L) 199 (146–271) 296 (211–413)c (n =3 8 )Cancer Chemother Pharmacol (2010) 65:563–570 567
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Table 2 Axitinib pharmacokinetic parameters for each ethnic group
AUCinf area under the plasma concentration–time curve from 0 h to inWnity, AUClast area under the plasma concentration–time curve from 0 h to
last quantiWable concentration, CI conWdence interval, Cmax maximal plasma concentration following single-dose administration, NA not applicable
a Arithmetic mean
b Ratio of axitinib in combination with rifampin versus axitinib alone
Parameter (units) Axitinib 5 mg (n =4 0 ) ,  
adjusted geometric mean
Axitinib 5 mg + rifampin 600 mg/day 
(n = 39), adjusted geometric mean
Ratio of adjusted means, 
%b (90% CI)
Caucasian
AUCinf (ng h/mL) 187 38 20 (16–25)
Cmax (ng/mL) 51.1 14.6 28.6 (21.6–37.7)
t1/2 (h)a 9.4 1.6 N/A
Japanese
AUCinf (ng h/mL) 193 41 21 (17–26)
Cmax (ng/mL) 49.2 14.5 29.4 (22.4–38.7)
t1/2 (h)a 6.0 3.3 N/A
Fig. 2 a Mean (§standard deviation) axitinib plasma concentration
proWle in Japanese (closed symbols) (n = 20) and Caucasian (open
symbols) (n = 20) subjects after administration of axtitinib, 5 mg single
dose, alone (Inset same plot with y-axis log scale) b Mean (§standard
deviation) axitinib plasma concentrations observed over time in Japa-
nese (closed symbols) (n = 20) and Caucasian (open symbols) (n = 19)
subjects in the presence of rifampin (Inset log scale)
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as shown in Fig. 2a. In subjects administered axitinib and
rifampin in combination, axitinib mean peak plasma con-
centrations were observed at 1.5 h after dosing in both eth-
nic groups (Fig. 2b). Figure 3a, b compares the AUCinf and
Cmax, respectively, of axitinib in Caucasian and Japanese
volunteers in the presence and absence of rifampin and
demonstrate no diVerences. Inter-subject variability for axi-
tinib AUCinf measured by coeYcient of variation was simi-
lar in Japanese and Caucasian subjects at 65 and 54%,
respectively.
EVect of UGT1A1 genotype on axitinib pharmacokinetics
During the 6-month enrollment period of the study, recruit-
ment was kept open in an eVort to enroll at least three Cau-
casian and three Japanese subjects who were variant for the
UGT1A1*28 allele. Of the 40 subjects eventually recruited
over the enrollment period, three Caucasian and one Japa-
nese subject were homozygous variant for UGT1A1*28. In
both Caucasian and Japanese subjects, pharmacokinetic
parameters (AUCinf and Cmax) were similar for subjects
with all UGT1A1*28 genotypes as shown in Fig. 4a and b
respectively.
Safety
None of the AEs were treatment-related or resulted in treat-
ment discontinuation, dose reduction, or death during the
study. No clinically relevant mean changes in hematology,
vital sign or ECG Wndings were noted in the overall safety
population or in either ethnic groups.
Discussion
The results of this study demonstrate three important Wnd-
ings. First, as expected, axitinib exposure is decreased
when concomitantly administered with rifampin in healthy
volunteers. Second, there is no diVerence in the plasma
pharmacokinetics of axitinib in healthy Caucasian and
Japanese subjects. Third, UGT1A1*28 polymorphism does
not appear to aVect the pharmacokinetics of axitinib.
The ratio of urinary 6, -hydroxycortisol/cortisol has
been used previously as a measure of CYP3A4 induction
[23]. In this study, the ratio of urinary 6, -hydroxycortisol/
cortisol concentrations in subjects was consistent with
maximal induction of CYP3A4 and returned to normal fol-
lowing washout after the end of rifampin dosing. The maxi-
mally observed eVect was similar between Japanese and
Caucasian subjects after 8 days of rifampin dosing. In addi-
tion, there was no diVerence in the 6, -hydroxycortisol/
cortisol ratios between Caucasian and Japanese subjects.
These results are consistent with eVective CYP3A
induction with rifampin in both Caucasian and Japanese
subjects.
Results from this study indicate that geometric mean
AUCinf and Cmax for axitinib were decreased by 79 and
71%, respectively, when co-administered with rifampin.
Induction of CYP3A4 with rifampin 600 mg/day has been
demonstrated in previous studies using the ratio of 6,
-hydroxycortisol/cortisol in urine [23]. In addition, rifam-
pin has also been shown to induce UGT1A1 and other
drug-metabolizing enzymes in clinical studies [11,  24].
Induction of axitinib metabolism as mediated by CYP3A4
in healthy, non-smoking volunteers resulted in a substantial
decrease in axitinib plasma concentration. This study there-
fore provides the lower bound for (minimum) plasma
concentrations expected following an oral dose of 5 mg
axitinib, i.e., in the presence of a potent metabolic inducer.
Fig. 4 Comparative box plot of axitinib a area under the plasma
concentration–time curve from 0 h to inWnity (AUCinf, ng h/mL)
b maximal plasma concentration (Cmax, ng/mL) in UGT1A1*28 wild
type (6/6, n = 23), heterozygous (6/7, n = 13), and variant (7/7, n =4 )
subjects. Data provided in this Wgure are following administration of
axitinib alone (i.e., in the absence of rifampin). Box plot represents 25th
and 75th percentiles, whiskers extend to 5th and 95th percentiles. Median
is indicated by line within box. Circles represent values for each subject
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First-generation Japanese subjects recruited in this study
were required to have been born in Japan, not lived outside
of Asia for more than 5 years, and should have had both
parents of Japanese descent. Ethnic diVerences in axitinib
pharmacokinetics between Japanese and Caucasian sub-
jects were minimal; the geometric mean ratios for axitinib
AUCinf and Cmax were not statistically diVerent between
Caucasian and Japanese subjects and pharmacokinetic
parameters were similar between the subjects, indicating
that these ethnicities do not contribute signiWcantly to the
axitinib pharmacokinetic variability observed in this study.
In addition, safety data were similar for Caucasian and
Japanese subjects.
Previous in vitro studies with human liver microsomes
have indicated the involvement of UGT1A1 in the glucu-
ronidation of axitinib, and so the eVect of the UGT1A1*28
genotype on axitinib pharmacokinetics was also explored in
Caucasian and Japanese subjects. Subjects who are variant
for UGT1A1*28 have the potential for reducing glucuroni-
dation of axitinib. The frequency of variant UGT1A1*28 is
12% (range 9–16%) for Caucasians and 4% (range 1–6%)
for Japanese populations [12–22]. Although this study was
not statistically powered to detect genotype-mediated
changes, axitinib pharmacokinetic parameters were similar
across UGT1A1*28 genotypes and ethnicity, implying that
this genotype does not likely contribute to the axitinib phar-
macokinetic variability observed in this study.
Single-dose axitinib, alone or in combination with
rifampin, was well tolerated by healthy volunteers in
this study. Combination treatment with rifampin for
8 days did not produce any drug-related AEs. All
observed AEs were deemed not related to study drug by
the investigator. No serious or clinically signiWcant AEs
were reported.
Conclusions
A reduction in axitinib exposure is observed when co-
administered with repeated doses of rifampin. Concomitant
treatment with axitinib and potent inducers of CYP3A4
would require axitinib dose adjustment for optimal clinical
eYcacy. The similarity of axitinib pharmacokinetics in
Caucasian and Japanese subjects supports a common start-
ing dose and regimen in these populations.
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